MedTrace Logo

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

NCT00625846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2020-02-26

Study results available
· View outcomes & findings →

Summary

This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.

Conditions

  • Recurrent Thyroid Gland Carcinoma
  • Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
  • Stage III Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
  • Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7
  • Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7
  • Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7
  • Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
  • Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7
  • Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7
  • Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
  • Thyroid Gland Anaplastic Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Keith C Bible · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-22
Primary Completion
2018-12-21
Completion
2019-08-13

Countries

  • United States
  • Australia
  • China
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00625846 on ClinicalTrials.gov